Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Cash: 2010-2025

Historic Change in Cash for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to $26.6 million.

  • Heron Therapeutics' Change in Cash rose 261.01% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 290.03%. This contributed to the annual value of -$2.9 million for FY2024, which is 121.60% down from last year.
  • As of Q3 2025, Heron Therapeutics' Change in Cash stood at $26.6 million, which was up 1,064.48% from -$2.8 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Change in Cash registered a high of $131.4 million during Q2 2021, and its lowest value of -$69.0 million during Q4 2021.
  • Its 3-year average for Change in Cash is $2.5 million, with a median of -$2.1 million in 2024.
  • In the last 5 years, Heron Therapeutics' Change in Cash slumped by 790.50% in 2021 and then spiked by 1,069.87% in 2023.
  • Heron Therapeutics' Change in Cash (Quarterly) stood at -$69.0 million in 2021, then skyrocketed by 49.19% to -$35.1 million in 2022, then soared by 82.37% to -$6.2 million in 2023, then spiked by 100.99% to $61,000 in 2024, then skyrocketed by 261.01% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, -$2.8 million for Q2 2025, and -$6.5 million during Q1 2025.